FDA Grants Biogen’s Salanersen Breakthrough Therapy Status in Major Development for SMA Pipeline

Biogen Inc. (Nasdaq: BIIB) secured a significant regulatory milestone when the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its investigational antisense oligonucleotide, salanersen, for the treatment of spinal muscular atrophy (SMA). This development, announced on June 4, 2026, reflects the therapy’s potential to deliver substantial improvement over existing treatments.

The designation is supported by exploratory Phase 1b data showing clinically meaningful improvements in motor function and a sustained 75% reduction in neurofilament light chain levels—a marker of neuronal injury—in children with SMA who had received prior gene therapy. Half of the participants achieved at least one new World Health Organization motor milestone, and all maintained their pre-existing abilities. Adverse effects were generally mild to moderate, consisting chiefly of upper respiratory tract infections, fevers, and vomiting.

Biogen is moving swiftly to evaluate salanersen’s potential in three global Phase 3 trials. STELLAR‑1, already recruiting, evaluates treatment in presymptomatic infants under six weeks old. SOLAR, also recruiting, focuses on teens and adults with SMA regardless of prior treatment. STELLAR‑2, expected to begin recruitment in June 2026, will assess salanersen when administered about six months after onasemnogene abeparvovec therapy in infants diagnosed early.

Why It Matters

The Breakthrough Therapy designation may fast-track development, enabling intensified FDA interaction and potentially accelerated review pathways. Given the chronic, life-altering nature of SMA and the limitations in current treatment options, a once-yearly dosing regimen delivering meaningful improvements marks a promising advance.

Moreover, the designation underscores progress in Biogen’s rare neurology portfolio, differentiating salanersen from other pipeline assets by its regulatory momentum. Still, it’s important to recognize that this is not an approval. Continued success in Phase 3 trials will be necessary before the therapy can reach the market.

Investor Implications

While detailed market reactions have not been officially reported, the Breakthrough status alone signals a viable path forward for a therapy with transformational potential. This development merits close monitoring as Phase 3 data emerge.

As of October 7, 2026, Biogen shares traded at $222.15, down 0.35%. Any future changes in stock performance should be viewed in light of confirmed milestones from Stage 3 development, regulatory filings, or clinical readouts, rather than the designation alone.

In summary, the FDA’s recognition of salanersen as a Breakthrough Therapy marks the most consequential near-term catalyst for Biogen’s SMA program. With Phase 3 trials now underway or imminent, the next 12–18 months will be pivotal in determining whether salanersen advances toward becoming a new, once-yearly treatment for SMA.